The trajectory of companies tied to Viagra's past presents a complex investment picture . While the initial success generated substantial profits , generic competition have significantly eroded sales . Investing in associated pharmaceutical businesses now requires a discerning assessment of proprietary rights , evolving patient shifts , and the pos